News
Market Update
Eli Lilly's Foundayo Oral Weight-Loss Pill Sees Modest Early Uptake
Suhaib
Executive summary
Eli Lilly's newly launched oral weight-loss drug Foundayo recorded 3,707 prescriptions in its second week on the market, trailing significantly behind competitor Novo Nordisk's Wegovy, which had 18,410 prescriptions in its second week. Analysts expressed concern over the modest uptake, though Lilly has cautioned that early data may not be comprehensive.
What happened
Eli Lilly's oral obesity pill Foundayo, approved by the FDA on April 1 and broadly available since April 9, recorded 3,707 prescriptions in the week ended April 17—its second full week on the market. This represented an increase from 1,390 prescriptions in its debut week. The prescription data, sourced from IQVIA and shared by Wall Street analysts, showed Foundayo's uptake at roughly 20% of what Novo Nordisk's competing oral Wegovy achieved during its first full week. Wegovy, which launched in January, had clocked 18,410 prescriptions in its second week and 3,071 in its first four days. Analysts characterized Foundayo's performance as modest and noted it fell short of expectations, with some hoping for closer to 8,000 prescriptions in week two. Lilly has previously cautioned that early weekly figures may not capture the full breadth of pharmacy partners and should be interpreted over time rather than as complete counts.
Why it matters
The early prescription data is significant because investors are closely watching Foundayo's rollout as a test of whether Lilly can capture market share from Novo Nordisk, which has established a first-mover advantage in the oral obesity drug market. The obesity treatment category has been a major growth driver for both companies, with Lilly's injectable Zepbound already proving successful. A slower-than-expected start for Foundayo raises questions about Lilly's ability to compete in the oral formulation space, where Wegovy's earlier launch and brand recognition provide competitive advantages. Analysts noted the uptake is likely to be received negatively by the market, and Lilly shares declined nearly 4% following the data release while Novo shares rose about 6%.
Bigger picture
The oral obesity drug market represents the next frontier in weight-loss treatments, with both pharmaceutical giants racing to offer patients convenient pill alternatives to their successful injectable products. Novo Nordisk gained first-mover advantage with Wegovy's December approval, while Lilly entered the market months later with Foundayo. The competitive dynamic mirrors the earlier injectable obesity drug race, where Lilly's Zepbound successfully challenged Novo's injectable Wegovy despite being a second mover. However, the oral market may prove different, as early brand recognition and time-to-market appear to be giving Novo an edge. The broader obesity drug category remains one of the fastest-growing pharmaceutical markets, with analysts projecting it could reach tens of billions in annual sales.
What to watch
Investors should monitor Foundayo's prescription trends over the coming weeks and months to determine whether the drug's uptake accelerates as availability expands and awareness builds. Key indicators include weekly prescription growth rates, market share gains versus Wegovy, and whether Lilly's extensive distribution network through LillyDirect and retail pharmacies helps close the gap. Additionally, watch for any company commentary on launch dynamics, expanded insurance coverage, or marketing initiatives that could boost adoption. Comparative data on patient persistence and switching patterns between the two oral products will also provide insight into longer-term competitive positioning.
This article was generated by Quantli AI using publicly available news sources.
